Product Description
Mechanisms of Action: 5-HT3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Simbec Research
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Testicular Cancer|Seminoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| SIMBEC-RD526/21494 | P3 |
Unknown status |
Testicular Cancer|Seminoma |
None |
2024-10-16 |
Recent News Events
Date |
Type |
Title |
|---|